This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Look: Discussing the recent announcement from Lilly regarding Lebrikizumab monthly maintenance dosing maintained durable skin clearance in their Phase 3 monotherapy atopic dermatitis trials

Ticker(s): LLY

Who's the expert?

Institution: Dermatology Associates of Western Connecticut.

*Has prescribed Adbry 1x so far

Dr. Jeffrey Knispel was born and raised in Brooklyn, New York. He received a Bachelor of Science degree in neurobiology from Cornell University in 1991. In 1995, he graduated from The Mount Sinai School of Medicine in New York. After completing an internship in pediatrics at The Mount Sinai Hospital (1996), Dr. Knispel did a residency in dermatology at The University of Chicago Hospitals from 1996 to 1999 where he served as chief resident. He was board certified by the American Board of Dermatology in 1999 and re-certified in 2008 and 2019. Dr. Knispel is a Fellow of the American Academy of Dermatology, as well as a member of the Connecticut Dermatology & Dermatologic Surgery Society, the New England Dermatologic Society, the Fairfield County Medical Association, and the Connecticut State Medical Society. Currently, he is on staff at Danbury Hospital and New Milford Hospital. He also holds the position of Assistant Clinical Professor of Dermatology in the Yale University School of Medicine.

 

Dr. Knispel’ s professional special interests include the treatment of skin cancer and pediatric dermatology. His other interests include performing cosmetic procedures such as laser surgery, Botox, and the injections of fillers.

Interview Goal
This call will focus on Lilly's recent announcement of results from the Adjoin trial provided durable efficacy in skin and itch outcomes through two years of treatment with both monthly and two-week dosing - nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost clear skin with lebrikizumab.

Do you want answers to these questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.